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Introduction: The objective of this cross-sectional and retrospective cohort study was (1) to determine the usefulness
of intima-media thickness (IMT) in contrast to plaque assessment, (2) to examine the value of additive femoral artery
sonography and (3) to identify potential risk factors for atherosclerosis and incident cardiovascular events in systemic
sclerosis (SSc) and systemic lupus erythematosus (SLE) patients.
Methods: In this study, 90 SSc and 100 SLE patients were examined by duplexsonography. IMT was measured in
common carotid and common femoral arteries, plaques were assessed in common, internal and external carotid and
common, proximal superficial and deep femoral arteries. Different definitions of pathological IMT (pIMT) were
compared with the presence of plaque. Results were evaluated in relation to traditional and non-traditional risk factors
for baseline atherosclerosis (logistic regression) and their predictive value for cardiovascular events during follow-up
(cox regression).
Results: Definite atherosclerosis occurred frequently without signs of subclinical atherosclerosis in both diseases:
pIMT >0.9 mm was present in only 17/59 (28.9%) SSc and 13/49 (26.5%) SLE patients with already present
atherosclerotic plaques. Using age-adjusted pIMT definitions, this rate was even lower (5.1-10.3% in SSc, 14.3-26.5% in
SLE). Plaques were located only at the carotid or only at the femoral arteries in 26 (13.7%) and 24 (12.6%) patients,
respectively. Age and nicotine pack-years were independently associated with atherosclerotic plaques in SLE and SSc
patients, as well as the cumulative prednisolone dose in SSc subgroup, and ssDNA positive SLE patients had a lower risk
for atherosclerotic plaque. During follow-up (available for 129/190 (67.9%) patients, 650 person-years), cardiovascular
events occurred more often in patients with coronary heart disease (adjusted-hazards ratio (HR) 10.19, 95% confidence
interval (CI) 3.04 to 34.17, P <0.001), male patients (adjusted-HR 8.78, 95% CI 2.73 to 28.19, P <0.001) and in patients with
coexistent carotid and femoral plaques (adjusted-HR 5.92, 95% CI 1.55 to 22.67, P = 0.009). Patients with solely carotid or
femoral plaque were not at higher risk.
Conclusion: Atherosclerotic plaque lesions can be found frequently in absence of intima-media thickening in both SSc
and SLE patients. As well as routine sonography of carotid arteries, the sonography of femoral arteries is recommended
to identify additional atherosclerotic lesions and to detect patients at a high risk for cardiovascular events.* Correspondence: m.frerix@kerckhoff-klinik.de
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Several studies have reported different findings with re-
spect to subclinical atherosclerosis (that is, pathologic
thickened intima-media) and definite atherosclerotic le-
sions (that is, plaque) in connective tissue diseases [1-15].
Recently, two meta-analyses and reviews revealed a
higher carotid intima-media thickness (cIMT) compared
with healthy controls in both systemic sclerosis (SSc) pa-
tients and systemic lupus erythematosus (SLE) patients
[1,2]. The majority of included studies limited duplexsono-
graphic examination to the common carotid artery (CCA)
for intima-media thickness (IMT) measurement. However,
atherosclerotic plaques are often present at the section
from the bulb to the internal carotid artery (ICA). There-
fore, it is unclear whether several studies, which primarily
focused on subclinical atherosclerosis, failed to detect
already present atherosclerotic plaques.
Interestingly, in contrast to the results of the meta-
analyses mentioned above, all large lupus studies in which
atherosclerotic assessment was extended to segments dis-
tal to the CCA found a lower or a normal cIMT but a sig-
nificantly higher rate of atherosclerotic plaques compared
with age-matched and sex-matched controls [3-5]. Add-
itionally, a decrease in small artery elasticity in SLE pa-
tients was observed without an increase of cIMT [6].
Hence, from these results atherosclerotic lesions seem to
occur independently of subclinical atherosclerosis in SLE.
An increased prevalence of coronary heart disease in
SSc patients was reported recently [7], but controversy
remains as to whether accelerated atherosclerosis is a
feature of SSc [8,9]. In one larger cohort of SSc patients,
IMT or plaque frequency was not significantly different
from controls [10], but whether the frequency of athero-
sclerotic plaque was underestimated by exclusion of ICA
and external carotid artery (ECA) segments and an un-
usual strict definition of plaque is unclear. In contrast,
another larger cohort revealed no difference in IMT but
an increased prevalence of atherosclerotic plaques in ca-
rotid arteries (data published as abstracts only, details of
IMT and plaque assessment unknown) [11,12]. More-
over, other available data from small SSc cohorts revealed
conflicting results regarding cIMT and a low frequency of
atherosclerotic plaques, but may be biased when ultra-
sound examination was limited to CCA [13,14]. In con-
trast, only in one available study extending the assessment
of atherosclerotic plaques to all carotid artery segments
(bilateral common, ICA and ECA) as well as vertebral ar-
teries was a significantly higher rate of definite atheroscler-
otic lesions in SSc patients found [15].
Unknown state of premature atherosclerosis is of sub-
stantial interest for the affected patients, because Belcaro
and colleagues previously showed in nonconnective tissue
diseases that carotid and femoral artery lesions have a com-
parable power in predicting cardiovascular events (CVEs)[16]. Notably, the assessment of all four arteries pre-
dicted more events than scans of only carotid, only fem-
oral arteries or only one side. There is only limited
information on whether the femoral artery is affected by
atherosclerosis in SLE [17], and studies searching for
femoral artery plaques in SSc are lacking. CVEs were
evaluated in several lupus cohort studies [18-20] and
one SSc cohort study [21], but cohort studies including
femoral artery duplexsonography are lacking.
Based on the potential impact of atherosclerosis on mor-
bidity and mortality of SLE patients and SSc patients, our
cross-sectional duplexsonography study of carotid and
femoral arteries and retrospective cohort study of CVEs
was designed to determine the usefulness of intima-media
measurement in contrast to atherosclerotic plaque detec-
tion, to assess the value of femoral artery additive to ca-
rotid artery sonography for identification of patients at
risk for incident CVEs, and to evaluate potential trad-
itional and nontraditional risk factors associated with
baseline atherosclerosis as well as their predictive value for
incident CVEs during follow-up in both patient groups.
Methods
Patients
We retrospectively identified 90 consecutive SSc patients
and 100 SLE patients from the inpatient and outpatient
clinics of the Department of Dermatology, Venerology,
and Allergology, University of Bochum, St Josef-Hospital
Bochum and the Department of Nephrology and Rheuma-
tology, Marienhospital Herne, University of Bochum be-
tween June 2004 and December 2006 to be eligible: SSc
patients had to meet the criteria reported by LeRoy and
Medsger [22] (and were subclassified into respective sub-
sets: limited cutaneous SSc, n = 51; diffuse cutaneous SSc,
n = 39) and SLE patients had to fulfill the American College
of Rheumatology criteria [23]. Detailed characteristics of
SSc and SLE patients are presented in Table 1.
The study was conducted in accordance with the Dec-
laration of Helsinki and guidelines of the local ethics
committee of the Ruhr-University Bochum (separate
ethics approval was not needed for this retrospective
study according to the local ethics committee regula-
tions). All data analyzed are based on routine clinical
examination; no patient underwent additional examin-
ation procedure for the purpose of this study. Written
informed consent was obtained from all patients for the
use of clinical and duplexsonography data, and the use
of blood samples for observational research purposes.
Ultrasound examination
Baseline ultrasound examinations of carotid and femoral
arteries of all 190 SLE and SSc patients were performed by
two experienced investigators (JS and SMW) at the Depart-
ment of Nephrology and Rheumatology, Marienhospital
Table 1 Baseline characteristics of systemic sclerosis and systemic lupus erythematosus patients
Characteristic Systemic sclerosis (n = 90) Systemic lupus erythematosus (n = 100)
Female 78 (86.7%) 87 (87%)
Age (years) 57.7 ± 14.4 48.1 ± 15.1
Disease duration (months) 85.0 ± 96.0 69.6 ± 92.0
Body mass index 24.5 ± 4.0 25.2 ± 4.7
Adipositas, body mass index >30 6 (6.7%) 14 (14%)
Hypertension 45 (50%) 56 (56%)
Systolic blood pressure (mmHg) 129.9 ± 23.2 130.6 ± 21.5
Diastolic blood pressure (mmHg) 75.9 ± 11.5 77.6 ± 10.6
Mean number of antihypertensives 0.8 (0, 4) 0.9 (0, 6)
Diabetes 4 (4.4%) 6 (6%)
Pulmonary hypertension 17 (18.9%) 3 (3%)
Coronary heart disease 10 (11.1%) 9 (9%)
Peripheral artery vessel disease 5 (5.6%) 2 (2%)
Nicotine use, current or former 43 (47.8%) 53 (53%)
Nicotine pack-years 10.7 ± 19.5 10.4 ± 16.2
Triglyceride (mg/dl) 139.2 ± 84.9 128.1 ± 69.9
Cholesterol (mg/dl) 216.5 ± 50.2 213.9 ± 59.6
Low density lipoprotein (mg/dl) 125.5 ± 39.2 123.7 ± 46.8
High density lipoprotein (mg/dl) 63.7 ± 18.7 64.4 ± 17.9
Family history of cardiovascular disease 12 (13.3%) 16 (16%)
Mean Rodnan skin score (median, range) 11 (9, 43) –
Mean SLEDAI (median, range) – 11 (9, 60)
Mean SLICC (median, range) – 2 (2, 8)
Values are mean ± standard deviation, number (percentage), or median (range).
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics damage index.
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Sequoia 512 Ultrasound system (Siemens Medical Solu-
tions, Erlangen, Germany) equipped with an 8 L5 linear
transducer. Examinations were performed at 8.0 MHz for
extracranial carotid and femoral arteries in several longitu-
dinal and transversal section views to assess IMT and to
identify atherosclerotic plaques (B-mode and color-coded
duplexsonography). To avoid interobserver bias and be-
cause sonography examiners were not blinded for diagnosis
in the routine clinical setting, the recorded anonymous im-
ages were evaluated only by one investigator (MF) without
knowledge of patient data and characteristics.
Carotid artery assessment of intima-media thickness and
atherosclerotic plaques
We documented the mean of six IMT measurements at
the far wall of the CCA over a 1 cm long segment, 1 to
2 cm proximal to carotid bifurcation for both sides. We
compared the power of left and right IMT values and
documented a mean IMT of the CCA as the mean of 12
measurements among both sides. The areas of plaque
were not included in the IMT assessment. Because theterm pathologic intima-media thickening (pIMT) for
assessment in the CCA is widely used but not well de-
fined, we compared three different definitions of pIMT: a
European version (pIMT > 0.9 mm) [24], a German ver-
sion (men 40 to 70 years old, pIMT > 1.0 mm; women 40
to 54 years old, pIMT > 0.85 mm and 55 to 70 years old,
pIMT > 1.0 mm) [25], and an Atherosclerosis Risk in
Communities (ARIC) version, defined by the 90th per-
centile for different age and sex groups out of the ARIC
cohort [26]. To apply the most sensitive definition of
pIMT, a patient was diagnosed to have pIMT of the CCA
when the left or right IMT CCA fulfilled these conditions
(even when the mean of left and right IMT CCA was
lower). Additionally, a focal thickening of intima-media
that did not fulfill the definition of plaque might have ful-
filled the definition of pIMT.
We screened the arteries for carotid plaques in com-
mon, internal and external carotids. According to the
Mannheim cIMT consensus, a plaque was defined as a
focal thickening of intima-media >0.5 mm or 50% of sur-
rounding intima-media into the arterial lumen, or a focal
thickening >1.5 mm [27].
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atherosclerotic plaques
Analog to the assessment of mean IMT of the CCA, the
mean IMT of the common femoral artery (CFA) was cal-
culated as the mean of 12 IMT measurements at the far
wall of the CFA (six at each side). Plaques were investi-
gated with respect to the common, proximal superficial
and deep femoral artery on both sides. Because femoral ar-
tery IMT measurement is not routinely performed, normal
or rather pathologic IMT values as well as a definition of
plaque are not given particularly for femoral arteries. Fem-
oral artery plaque was thus defined similar to carotid artery
plaque as a focal thickening of intima-media >0.5 mm or
50% of surrounding intima-media into the arterial lumen,
or a focal thickening >1.5 mm [27]. In addition, we used
and compared the definitions of pIMT and atherosclerotic
plaque as given for carotid arteries with the findings at the
femoral arteries.
Assessment of traditional cardiovascular risk factors
for atherosclerosis
The assessed traditional risk factors for atherosclerosis were
age, sex, body mass index, arterial hypertension, diabetes
mellitus, smoking (current or former and pack-years), dys-
lipidemia and family history of cardiovascular disease.
Blood pressure levels were evaluated as the mean of left
and right brachial artery measurements after at least 5 mi-
nutes of rest or (whenever possible) by 24-hour outpatient
blood pressure measurement. Hypertension was defined by
blood pressure >140/90 mmHg or use of antihypertensive
drugs. In cases when a calcium channel blocker was pre-
scribed for secondary Raynaud phenomenon, we did not
rate this as antihypertensive drug use, except if arterial
hypertension was documented previously and the calcium
antagonist was given to treat hypertension and Raynaud
phenomenon at the same time. Dyslipidemia was defined
by elevated plasma cholesterol (>200 mg/dl for age 18 to
29 years; >220 mg/dl for age 30 to 40 years; >240 mg/dl for
age >40 years), plasma low-density lipoprotein cholesterol
(>160 mg/dl) and/or plasma triglyceride (>200 mg/dl)
levels, or use of lipid-lowering drugs such as HMG co-
inhibitors [28]. Plasma high-density lipoprotein cholesterol
levels were assessed as a protective vascular factor.
Assessment of potential nontraditional and
disease-related determinants for atherosclerosis
We evaluated the following nontraditional and disease-
related determinants as potential risk factors associated
with accelerated atherosclerosis: in SLE patients, disease ac-
tivity was assessed by the Systemic Lupus Erythematosus
Disease Activity Index score (SLEDAI) [29] and disease
damage was assessed by the Systemic Lupus International
Collaborating Clinics damage index score (SLICC) [30].
In SSc patients we evaluated the modified Rodnan skinscore [31]. Organ involvement was recorded including
Raynaud phenomenon, pulmonary hypertension, coronary
heart disease and peripheral arterial vascular disease (de-
fined by obstructive vessel disease with claudicatio intermit-
tens). We also assessed family history of connective tissue
diseases, disease duration since diagnosis and age at
diagnosis.
Previous immunosuppressive treatment was determined,
such as use of prednisolone (duration of treatment, mean
daily dose in the last 5 years and cumulative dose), hydro-
xychloroquine (HCQ), azathioprine (AZA) and cyclophos-
phamide (CYP) (duration of treatment and cumulative
dose, if applicable). Sufficient data for duration of cortico-
steroid (CS) treatment were given in 96.8% of patients and
for cumulative CS dose in 92.4% of patients. For duration
of use and cumulative dose of HCQ, AZA and CYP, data
were adequate in 99.5%, 98.4% and 99.5% of patients,
respectively.
Routine laboratory assessment included C3c and C4c
as disease activity markers for SLE patients, as well as
C-reactive protein. Renal function was given by the
glomerular filtration rate (Mayo formula). For analysis
of the potential role of different autoantibodies, blood
samples of all patients were tested by standard immuno-
fluorescence test using Hep2 cells for antinuclear anti-
bodies and by enzyme-linked immunosorbent assay
(Euroimmune, Lübeck, Germany) for the following auto-
antibodies: double-stranded DNA (dsDNA), single-
stranded DNA (ssDNA), Sm, C1q, SS-A, SS-B, U1RNP,
Pm-Scl, RNP, RIP-PP, nucleosomes, centromeres, Scl-70
and antiphospholipid antibodies (cardiolipin IgG and IgM,
β1-glycoprotein-1 IgG and IgM, lupus anticoagulans).
Follow-up assessment of cardiovascular events
Patients were followed up by routine clinical visits at the
Department of Dermatology, Venerology, and Allergology,
University of Bochum. To compare the predictive value of
pIMT, carotid and femoral artery plaques for CVEs, a re-
view of patient records until December 2011 (5 years after
baseline of the last included patient) was performed. CVEs
were defined as coronary events (new angina pectoris or
myocardial infarct requiring treatment), cerebrovascular
events (transient ischemic attack or stroke), peripheral ar-
terial vascular events (claudicatio intermittens, ischemic
pain due to embolization) or death related to cardiovascu-
lar disease.
Statistical methods
Baseline analysis of carotid and femoral artery
duplexsonography assessment and potential risk factors for
atherosclerosis (cross-sectional study)
Characteristics of SSc patients and SLE patients were de-
scribed by univariate statistics. For comparison of mean
IMT between the CCA and the CFA, we used a paired
Frerix et al. Arthritis Research & Therapy 2014, 16:R54 Page 5 of 17
http://arthritis-research.com/content/16/1/R54Student t test. The McNemar test was used to compare
the frequency of carotid and femoral artery plaques. Dif-
ferent definitions of pathologic IMT were compared with
the presence of atherosclerotic plaque in the whole cohort
by descriptive statistics. Pearson correlation coefficients
and phi coefficients are reported for correlation of poten-
tial risk factors for atherosclerosis with CCA and CFA
IMT. For comparison of scale variables between patients
with and without atherosclerotic plaque we used a two-
sided Student t test, for non-normally distributed variables
we used the Mann–Whitney U test. For comparison of
categorical variables we used the chi-square test, or
Fisher’s exact test if conditions were not confirmed.
Additionally, to assess factors independently associated
with atherosclerosis, a multivariate linear regression ana-
lysis was performed for mean IMT of the CCA and the
CFA, and a binary logistic regression analysis was per-
formed for atherosclerotic plaque. Covariates for regres-
sion analyses were selected based on clinical knowledge
and from potentially associated variables in explorative
baseline analysis; model building was performed taking
care of statistical considerations such as a suitable number
of events per variable and the number of observations (ob-
servations with missing values were excluded from ana-
lyses). Competing models fit to the same set of data were
compared using R2 measures (linear model), Nagelkerke’s
pseudo-R2 and a likelihood ratio test (logistic model). The
R2 value, constant, beta coefficients with 95% confidence
intervals (CIs) and standardized beta coefficients were
reported for the final chosen model of multivariate linear
regression analysis; pseudo-R2 value, constant, beta coeffi-
cients and odds ratios with 95% CIs were stated for the
final chosen model of binary logistic regression analysis.
The goodness-of-fit of the logistic model was evaluated by
Hosmer–Lemeshow test. To improve ease of interpret-
ation of the continuous variables in the final logistic model
(age, nicotine pack-years, prednisolone intake and AZA
use), they were reported as 5-year increments.
Longitudinal analysis of cardiovascular events during the
follow-up period (retrospective cohort study)
The risk of CVEs during follow-up for patients with pres-
ence of carotid and femoral artery plaques was compared
with patients with only carotid or femoral artery plaque,
as well as with patients without atherosclerotic plaques re-
ported as rate ratio estimates with 95% CIs based on the
incidence density rate (IDR; CVEs per person-years), using
the Kaplan–Meier method to graph and the log-rank test
to compare (unadjusted) survival curves for the time to
first CVE. Additionally, the Cox proportional-hazards re-
gression model was used to estimate unadjusted and ad-
justed hazard ratios (HRs) with 95% CIs for possible risk
factors predictive of CVEs. Competing models were com-
pared using the likelihood ratio test, and assumption ofproportional hazards was confirmed by log-minus-log sur-
vival plots. Because the HR of patients with only carotid
or femoral artery plaque and of patients without athero-
sclerotic plaque was nearly one, the polytomous variable
for plaque (reported in Cox model 1) was dichotomized to
build a parsimonious final "best" model (reported in Cox
model 2). In the end, we built a Cox model using only the
information of plaques at the level of carotid arteries to es-
timate the adjusted hazard of patients with carotid plaque
in a hypothetical scenario in which screening of femoral
arteries was not performed.
Statistical analysis was performed using PASW Statistics,
Version 18 (SPSS Inc., Chicago, USA) and IBM SPSS Sta-
tistics, Version 21 (IBM, New York, USA).
Results
Comparison of baseline carotid and femoral artery
duplexsonography results in systemic sclerosis patients
Comparison of carotid and femoral artery intima-media
thickness in systemic sclerosis patients
IMT was highly correlated between left and right sides
at the level of the CCA (r = 0.880; P < 0.001) as well as
the CFA (r = 0.811; P < 0.001). The correlation between
IMT of the CCA and IMT of the CFA was much weaker
(r = 0.508; P < 0.001). There was no significant difference
between mean CCA IMT and CFA IMT (0.76 ± 0.15 mm
vs. 0.78 ± 0.18 mm; P = 0.170), or between left and right
CCA IMT (0.75 ± 0.15 mm vs. 0.75 ± 0.16 mm; P =
0.707) or left and right CFA IMT (0.78 ± 0.19 mm vs.
0.77 ± 0.19 mm; P = 0.398).
Comparison of carotid and femoral artery definitive
atherosclerosis (plaques) in systemic sclerosis patients
A total of 84 carotid artery plaques and 90 femoral artery
plaques were detected in 59 SSc patients. Thirty-five carotid
artery plaques were found in 27 patients (30%) on the left
side compared with 49 plaques in 36 patients (40%) on the
right side (P = 0.123). The distribution of carotid artery pla-
ques according to the CCA, the region of the bulb, ICA
and ECA is shown in Figure 1. In 9 to 18 patients (10 to
20%) carotid plaques would not have been detected if ca-
rotid ultrasound examination was limited to one side.
Forty-three femoral artery plaques were found in 36 pa-
tients (40%) on the left side and 47 plaques in 39 patients
(43.3%) on the right side (P = 0.646). In 8 to 23 patients (8.9
to 25.6%) the plaques would have been missed if femoral
ultrasound examination was limited to one side. Twenty-
six patients (28.9%) had atherosclerotic plaques in only one
of the four vascular territories. The overall frequency of ca-
rotid and femoral artery plaques was not different (50% vs.
52.2%; P = 0.845), but the plaque distribution varied in indi-
vidual patients: in 12 patients (13.3%), plaque was only lo-
cated at the carotid arteries; in 14 patients (15.6%), plaque
was observed isolated at femoral arteries. In approximately
Figure 1 Distribution of carotid artery plaques in our cohort of systemic sclerosis and systemic lupus erythematosus patients. Carotid
artery plaques are mostly located at the internal carotid artery (ICA) and the region of the bulb, and are rarely observed at the external carotid
artery (ECA) and the common carotid artery (CCA). An extension of carotid ultrasound examination distal to the CCA segment for plaque
assessment is highly recommended.
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have been detected if routine ultrasonography was limited
to the carotid arteries.
Comparison of different pathologic intima-media definitions
for common carotid artery with the presence of atheroscler-
otic plaque in systemic sclerosis patients
There was a high incongruity in the presence of athero-
sclerotic plaques and a thickened intima-media (pIMT), in-
dependent of the criteria used to define pIMT (Table 2).
IMT > 0.9 mm was detected in only 17 out of 59 SSc pa-
tients (28.9%) with atherosclerotic plaques. Moreover, ac-
cording to the European definition as well as the German
definition, none of the patients without atherosclerotic pla-
ques had a pathologic intima-media. Using the ARIC defin-
ition (taking note of individual difference in IMT according
to sex and increasing IMT with age), 19.4% of SSc patients
without atherosclerotic plaques had pIMT. Subgroup ana-
lysis revealed that about 80% of SSc patients with baseline
cardiovascular disease had atherosclerotic plaques, in con-
trast to one-third of patients with pIMT (Table 3).
Association of potential risk factors with intima-media
thickness and atherosclerotic plaques in systemic
sclerosis patients
Correlation of traditional cardiovascular risk factors and
disease-related factors with intima-media thickness in
systemic sclerosis patients
Correlations between common carotid and femoral ar-
tery IMT with traditional and nontraditional risk factorsfor atherosclerosis are shown in Table 4 (and Additional
file 1). In multivariate analysis, age was independently
associated with IMT of the CCA and the CFA, whereas
male sex was associated with IMT of the CCA and the
CFA and decrease of renal function and smoking only
with IMT of the CFA (Table 5).
Association of traditional cardiovascular and
disease-related risk factors with presence of atherosclerotic
plaques in systemic sclerosis patients
Detailed results of univariate analysis are presented in
Table 6 (and Additional file 2). In multivariate analysis, age
and cumulative nicotine pack-years were significant inde-
pendent predictors for atherosclerosis and also cumulative
prednisolone dose remained a statistically significant pre-
dictor of atherosclerotic plaques in SSc patients (Table 7).
Comparison of baseline carotid and femoral artery
duplexsonography results in SLE patients
Comparison of carotid and femoral artery intima-media
thickness in SLE patients
As shown above in SSc patients we also found in SLE pa-
tients a high correlation of IMT between left and right
sides at the level of the CCA (r = 0.792; P < 0.001) and the
CFA (r = 0.870; P < 0.001). Again the correlation between
IMT of the CCA and IMT of the CFA was much weaker
(r = 0.476; P < 0.001). There was no significant difference
between mean IMT of the CCA and the CFA (0.70 ±
0.13 mm vs. 0.71 ± 0.15 mm; P = 0.215), or between left
and right IMT of the CCA (0.70 ± 0.14 mm vs. 0.70 ±
Table 2 Comparison of intima-media thickening with the presence of carotid or femoral atherosclerotic plaques
(whole cohort)
SSc and SLE patients with
and without plaque
European definition (pIMT > 0.9 mm) German definition (pIMT > 0.85/> 1.0 mm) ARIC definition (pIMT > P90)
SSc Without plaque (n = 31) 0 (0%) 0 (0%) 6 (19.4%)
With plaque (n = 59) 17 (28.9%) 3 (5.1%) 6 (10.3%)
SLE Without plaque (n = 51) 0 (0%) 0 (0%) 3 (5.9%)
With plaque (n = 49) 13 (26.5%) 7 (14.3%) 13 (26.5%)
Values presented as number of patients with pIMT (percentage).
pIMT, pathologic intima-media thickening; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
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(0.72 ± 0.15 mm vs. 0.71 ± 0.15 mm; P = 0.225).
Comparison of carotid and femoral artery definitive
atherosclerosis (plaques) in SLE patients
In 49 SLE patients, a total of 89 carotid artery plaques and
69 femoral artery plaques were detected. Forty-seven ca-
rotid artery plaques were found in 31 patients on the left
side compared with 42 plaques in 33 patients on the right
side (31% vs. 33%, P = 0.789). The distribution of carotid
artery plaques according to the CCA, region of the bulb,
ICA and ECA is shown in Figure 1. In 6 to 8% of patients,
carotid plaques would have been not detected if carotid
ultrasound examination was limited to one side.
Thirty-four femoral artery plaques were found in 25 pa-
tients on the left side and 35 plaques in 30 patients on the
right side (25% vs. 30%, P = 0.301). In 5 to 12% of patients
the plaques would have been missed if femoral ultrasound
examination was limited to one side. Twenty-four patients
had atherosclerotic plaques in only one of the four vascular
territories. The overall frequency of carotid and femoral ar-
tery plaques was not different (39 vs. 35%, P = 0.541), but
plaque distribution varied in individual patients: in 14% of
patients, plaque was only located at the carotid arteries; inTable 3 Subgroup analysis of intima-media thickening and at
lupus erythematosus patients with cardiovascular disease
Subgroup of SSc and
SLE patients with
cardiovascular disease
Pathologic IMT
(any definition) Carot
femoral a
SSc patients
with
Arterial hypertension (n = 45) 16 (35.6%) 38
Pulmonary hypertension (n = 17) 6 (35.3%) 15
Coronary heart disease (n = 10) 2 (20%) 8
Peripheral artery vessel
disease (n = 5)
2 (40%) 4
SLE patients
with
Arterial hypertension (n = 56) 15 (26.8%) 39
Pulmonary hypertension (n = 3) 1 (33.3%) 3
Coronary heart disease (n = 9) 5 (55.6%) 9
Peripheral artery vessel
disease (n = 2)
1 (50%) 2
Values presented as number (percentage) of patients with pathologic intima-media
IMT, intima-media thickness; SLE, systemic lupus erythematosus; SSc, systemic scler10% of patients, plaque was observed isolated at femoral ar-
teries. Thus, in one out of 10 patients atherosclerosis would
have been not detected if routine ultrasonography was lim-
ited to the carotid arteries.
Comparison of different pathologic intima-media definitions
for the common carotid artery with the presence of
atherosclerotic plaque in SLE patients
There was high incongruity in the presence of atheroscler-
otic plaques and a pathologic thickened intima-media, in-
dependent of the criteria used to define pIMT. IMT >
0.9 mm was detected in only 13 out of 49 SLE patients
(26.5%) with atherosclerotic plaques. Moreover, according
to the European definition as well as the German defin-
ition, none of the patients without atherosclerotic plaques
had a pathologic intima-media. Using the ARIC definition
(taking note of individual difference in IMT according to
sex and increasing IMT with age), 5.9% of SLE patients
without atherosclerotic plaques had a pIMT. Subgroup
analysis revealed that all SLE patients with baseline coron-
ary heart disease, pulmonary hypertension and/or periph-
eral vascular disease have had atherosclerotic plaques, but
in contrast only one out of two or three patients had a
thickened intima media (Table 2).herosclerotic plaques in systemic sclerosis and systemic
Atherosclerotic plaque
id and/or
rtery plaque
Only carotid
artery plaque
Only femoral
artery plaque
Coexistent carotid and
femoral artery plaque
(84.4%) 7 (15.6%) 5 (11.1%) 26 (57.8%)
(88.2%) 0 (0%) 2 (11.8%) 13 (76.5%)
(80%) 0 (0%) 0 (0%) 8 (80%)
(80%) 1 (20%) 1 (20%) 2 (40%)
(69.6%) 10 (17.9%) 9 (16.1%) 20 (35.7%)
(100%) 1 (33.3%) 1 (33.3%) 1 (33.3%)
(100%) 1 (11.1%) 0 (0%) 8 (88.9%)
(100%) 0 (0%) 0 (0%) 2 (100%)
thickness and carotid or femoral artery plaque.
osis.
Table 4 Correlation of carotid and femoral artery intima-media thickness with traditional and nontraditional risk
factors for atherosclerosisa
Variable SSc (n = 90) SLE (n = 100)
Mean CCA IMT Mean CFA IMT Mean CCA IMT Mean CFA IMT
Correlation P value Correlation P value Correlation P value Correlation P value
Age (years) r = 0.682 <0.001 r = 0.565 <0.001 r = 0.726 <0.001 r = 0.560 <0.001
Age at diagnosis (years) r = 0.652 <0.001 r = 0.586 <0.001 r = 0.670 <0.001 r = 0.437 <0.001
Disease duration (months) r = −0.030 0.782 r = −0.109 0.308 r = 0.094 0.357 r = 0.217 0.032
Male sex rφ = 0.261 0.013 rφ =0.341 0.001 rφ = 0.268 0.007 rφ = 0.208 0.039
Postmenopausal status r = 0.546 0.001 r = 0.375 0.001 r = 0.400 <0.001 r = 0.373 <0.001
Body mass index r = 0.128 0.241 r = 0.197 0.070 r = 0.258 0.012 r = 0.294 0.004
Systolic blood pressure (mmHg) r = 0.303 0.007 r = 0.332 0.003 r = 0.346 0.001 r = 0.171 0.124
Glomerular filtration rate r = −0.316 0.003 r = −0.489 <0.001 r = −0.296 0.003 r = −0.277 0.006
Nicotine pack-years r = 0.022 0.839 r = 0.320 0.002 r = 0.082 0.424 r = −0.058 0.570
Coronary heart disease rφ = 0.160 0.133 rφ = 0.379 <0.001 rφ = 0.265 0.008 rφ = 0.160 0.115
mRSS r = 0.225 0.036 r = −0.021 0.843 – – – –
SCL70 antibody rφ = −0.117 0.270 rφ = −0.209 0.048 – – – –
Centromere antibody rφ = 0.165 0.119 rφ = 0.255 0.015 – – – –
SLEDAI – – – – r = −0.166 0.115 r = −0.057 0.591
SLICC – – – – r = 0.208 0.049 r = 0.117 0.271
dsDNA antibody – – – – rφ = −0.188 0.063 rφ = −0.197 0.051
Nucleosomes antibody – – – – rφ = −0.231 0.021 rφ = −0.123 0.224
CCA, common carotid artery; CFA, common femoral artery; dsDNA, double-stranded DNA; IMT, intima-media thickness; mRSS, modified Rodnan Skin Score; SLE, systemic lupus
erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics damage index; SSc, systemic sclerosis.
aOnly variables suggested for multivariate linear regression analysis are reported; complete report available in Additional file 1.
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thickness and atherosclerotic plaques in SLE patients
Correlation of traditional cardiovascular risk factors and disease-
related factors with intima-media thickness in SLE patients
Correlations between common carotid and femoral artery
IMT with traditional and nontraditional risk factors for ath-
erosclerosis are shown in Table 4 (and Additional file 1). In
multivariate analysis, no variable other than age was inde-
pendently associated with IMT of the CCA or CFA in SLE
patients and multivariate models performed no better thanTable 5 Linear regression analysis of factors associated with c
systemic sclerosis and systemic lupus erythematosus patients
Variable Mean CCA IMT
Standardized beta
coefficient
Regression coeffi
(95% CI)
Systemic sclerosisa (Constant 0.349; R2 = 50.5%
Age (per year) 0.664 0.007 (0.005 to 0.
Male sex 0.202 0.088 (0.022 to 0.
Glomerular filtration rate (per unit) – –
Nicotine use (per pack-year) – –
Systemic lupus erythematosusb (Constant 0.392; R2 = 52.7%
Age (per year) 0.726 0.006 (0.005 to 0.
CCA, common carotid artery; CFA, common femoral artery; CI, confidence interval; I
aMultivariate linear regression model for mean CCA IMT and CFA IMT of systemic sc
multivariate analysis did not significantly improve the model for both mean CCA IMsimple linear regression. Thus, instead of a multivariate lin-
ear regression model we reported the result of the simple
linear regression (Table 5).
Association of traditional cardiovascular and
disease-related risk factors with the presence of
atherosclerotic plaques in SLE patients
Detailed results of univariate analysis are presented in
Table 6 (and Additional file 2). Interestingly, in multi-
variate logistic regression analysis, beside the traditionalarotid and femoral artery intima-media thickness in
Mean CFA IMT
cient P value Standardized beta
coefficient
Regression coefficient
(95% CI)
P value
) (Constant 0.762; R2 = 49.9%)
008) <0.001 0.336 0.004 (0.002 to 0.007) 0.003
153) 0.012 0.245 0.138 (0.025 to 0.251) 0.018
– −0.302 −0.003 (0.000 to 0.004) 0.005
– 0.198 0.002 (0.000 to 0.004) 0.046
) (Constant 0.452; R2 = 31.3%)
008) <0.001 0.560 0.005 (0.004 to 0.007) <0.001
MT, intima-media thickness.
lerosis patients. bSimple linear regression model, other additional variables in
T and CFA IMT of systemic lupus erythematosus patients.
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pack-years, the duration of AZA use also seemed to be
independently associated with presence of atherosclerotic
plaque. Out of the autoantibodies, only ssDNA but not
dsDNA, nucleosomes or RNP antibodies stayed in the final
"best" model, and presence of ssDNA autoantibodies was in-
dependently associated with the absence of atherosclerotic
plaques (Table 7).
Longitudinal analysis of cardiovascular events during
follow-up in SSc and SLE patients
Overall, follow-up data of CVEs were available for 78/90
(87%) SSc patients and 51/100 (51%) SLE patients. During
the observational period of in a total 650.1 person-years
(mean 60.5 months, median 65.5 months, range 8 to
82 months), 24 CVEs were recorded in 19 out of 129 pa-
tients (15%): 13 events in 11/78 (14%) SSc patients (coronary
events, n= 7; peripheral arterial vascular events, n= 3; death
related to cardiovascular disease, n = 3) and 11 CVEs in
8/51 (16%) SLE patients (coronary events, n = 5; cerebrovas-
cular events, n= 3; peripheral arterial vascular events, n= 3).Table 6 Explorative baseline analysis of potential risk factors b
Characteristic SSc (n = 90)
With plaque Without plaq
(n = 59) (n = 31)
Age (years) 63.9 ± 12.0 45.9 ± 10.9
Male sex 10 (16.9%) 2 (6.5%)
Postmenopausal status, women only 44/49 (89.8%) 12/29 (41.4%
Hypertension 38 (64.4%) 7 (22.6%)
Nicotine pack-years 13.9 ± 22.5 4.1 ± 7.8
Dyslipidemia 30 (50.8%) 7 (22.6%)
Age at diagnosis (years) 56.0 ± 14.3 38.7 ± 10.9
Pulmonary hypertension 15 (25.4%) 2 (6.5%)
Coronary heart disease 8 (13.6%) 2 (6.5%)
Glomerular filtration rate 85.1 ± 19.7 101.3 ± 13.4
Autoantibodies
SCL70 12 (20.3%) 14 (45.2%)
Centromere 28 (47.5%) 8 (25.8%)
ssDNA – –
dsDNA – –
Nucleosomes – –
RNP – –
Immunosuppressive treatment:
Duration of CS use (months) 37.2 ± 61.6 13.1 ± 29.8
Cumulative CS dose (g) 8.0 ± 14.8 2.7 ± 7.5
Duration of AZA use (months) 10.0 ± 29.6 7.9 ± 27.7
Cumulative AZA dose (g) 29.4 ± 83.0 23.7 ± 83.0
Values presented as number of patients (percentage) or mean ± standard deviation
AZA, azathioprine; CS, corticosteroid; dsDNA, double-stranded DNA; SLE, systemic lu
aOnly variables suggested for logistic regression analysis are reported; complete repThe incidence of CVEs was 13 per 388.5 person-years (IDR
= 3.35 per 100 person-years) in SSc patients and 11 per
261.6 person-years (IDR= 4.2 per 100 person-years) in SLE
patients. Six patients (five SSc and one SLE) died due to
other causes (one after stem cell transplantation, one severe
pneumonia, one lung embolism, one breast cell cancer, one
suicide, one unknown cause).
According to pathologic IMT of the CCA, only 7/19
(36.8%) patients with CVEs had pIMT according to the
European definition (>0.9 mm), only 4/19 (21.1%) patients
would meet the ARIC definition, and merely 2/19 (10.5%)
patients the German definition of pathologic IMT.
According to the presence of plaque, CVEs were distrib-
uted as follows: 18 CVEs were observed within 183.75
person-years of follow-up (IDR = 9.8 per 100 person-years)
in 15 out of 40 patients (37.5%) that had both carotid and
femoral artery plaques; three CVEs per 200.6 person-years
(IDR = 1.5 per 100 person-years) occurred in 2/37 (5.4%)
patients that had only carotid (1/19, 5.2%) or only femoral
artery plaques (1/18, 5.6%); and three CVEs per 265.75
person-years (IDR = 1.1 per 100 person-years) in 2/52etween patients with or without atherosclerotic plaquesa
SLE (n = 100)
ue P value With plaque Without plaque P value
(n = 49) (n = 51)
<0.001 57.7 ± 10.6 39.0 ± 13.0 <0.001
0.206 11 (22.4%) 2 (3.9%) 0.007
) <0.001 31/38 (81.6%) 16/49 (32.7%) <0.001
<0.001 39 (79.6%) 17 (33.3%) <0.001
0.003 14.7 ± 20.6 6.2 ± 8.9 0.009
0.010 24 (49%) 15 (29.4%) 0.045
<0.001 50.8 ± 14.4 33.4 ± 11.4 <0.001
0.045 3 (6.1%) 0 (0%) 0.114
0.484 9 (18.4%) 0 (0%) 0.001
<0.001 89.0 ± 23.1 100.6 ± 24.3 0.019
0.014 – – –
0.046 – – –
– 10 (20.4%) 19 (37.3%) 0.063
– 11 (22.4%) 27 (52.9%) 0.002
– 7 (14.3%) 15 (29.4%) 0.068
– 4 (8.2%) 11 (21.6%) 0.092
0.016 25.1 ± 41.8 25.4 ± 57.0 0.978
0.030 7.5 ± 16.9 4.8 ± 8.3 0.335
0.747 21.8 ± 50.5 7.7 ± 25.2 0.086
0.763 83.9 ± 244.6 25.1 ± 79.6 0.115
.
pus erythematosus; SSc, systemic sclerosis; ssDNA, single-stranded DNA.
ort available in Additional file 2.
Table 7 Multivariate logistic regression analysis of predictors of atherosclerotic plaque in systemic sclerosis and
systemic lupus erythematosus patients
Variable Beta coefficient Odds ratio (95% CI) P value
Systemic sclerosis (n = 85)a
Age (per 5 years) 0.904 2.47 (1.61 to 3.78) <0.001
Nicotine use (per 5 pack-years) 0.554 1.74 (1.13 to 2.68) 0.012
Prednisolone intake (per 5 mg/day over 5 years) 0.940 2.56 (1.09 to 6.04) 0.032
Systemic lupus erythematosus (n = 98)b
Age (per 5 years) 0.824 2.28 (1.61 to 3.22) <0.001
Nicotine use (per 5 pack-years) 0.313 1.37 (1.05 to 1.78) 0.021
ssDNA antibody positive −1.613 0.20 (0.05 to 0.83) 0.026
Duration of azathioprine use (per 5 years) 0.947 2.58 (0.93 to 7.13) 0.068
CI, confidence interval; ssDNA, single-stranded DNA.
aFive observations excluded from model because of missing values. Events per variable: 27/3 = 9. Constant = −10.435. Nagelkerke R2 = 65.6%. Hosmer–Lemeshow
test P = 0.147. bTwo observations excluded from model because of missing values. Events per variable: 49/4 = 12.25. Constant = −8.507. Nagelkerke R2 = 65.2%.
Hosmer–Lemeshow test P = 0.914.
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http://arthritis-research.com/content/16/1/R54patients (3.8%) that had neither carotid nor femoral artery
plaques. The incidence rate of CVEs during follow-up was
thus significantly higher in patients with carotid and
femoral artery plaque compared with patients with only
carotid or only femoral artery plaque (rate ratio = 6.55,
95% CI = 1.9 to 22.2, P = 0.003) or compared with pa-
tients without atherosclerotic plaque (rate ratio = 8.68,
95% CI = 2.6 to 29.5, P < 0.001) (Figure 2). Patients with
only carotid plaque or only femoral plaque were not at9.8
(18 events / 183.75 py)
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Figure 2 Incidence and rate ratios of cardiovascular events during fol
cardiovascular events per 100 person-years (py) during follow-up available
median 65.5 months, range 8 to 82 months) according to the presence of car
for patients with carotid and femoral artery plaque in contrast to patients with
without plaque. CI, confidence interval.higher risk compared with patients without plaque (rate
ratio = 1.32, 95% CI = 0.3 to 6.6, P = 0.731).
Analysis of time to first CVE revealed that SSc and SLE
patients with coexistent carotid and femoral artery plaque
are at higher risk (Figure 3A,B). Results from univariate
analysis of potential predictors of CVEs during follow-up in
SSc and SLE patients are presented in Table 8.
In multivariate Cox regression analysis (model 1), the co-
existent presence of carotid and femoral artery plaque was1.5
s / 200.6 py) 1.1(3 events / 265.75 py)
otid or only 
rtery plaque
no carotid or femoral 
artery plaque
ding to the distribution of plaque
RR 8.68
95%CI 2.8-26.9
p < 0.001
low-up according to the presence of plaque. Incidence of
for 129/190 (67.9%) patients (650 person-years, mean 60.5 months,
otid and femoral artery plaque. The rate ratio (RR) was approximately 6.5
only one vascular segment affected and was 8.7 compared with patients
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Figure 3 Kaplan–Meier survival curves for the time to first cardiovascular event according to the presence of plaque. Kaplan–Meier
survival curves for the time to first cardiovascular event during follow-up and results of a log-rank test stratified by (A) systemic sclerosis (SSc) and
(B) systemic lupus erythematosus (SLE) according to the presence of carotid and femoral artery plaques. Group 1, patients without carotid or femoral
artery plaque; group 2, patients with only carotid or only femoral artery plaque; group 3, patients with coexistent carotid and femoral artery plaque.
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http://arthritis-research.com/content/16/1/R54predictive for CVEs during follow-up compared with
patients without plaque (adjusted HR= 6.13, 95% CI = 1.27
to 29.53, P = 0.024) whereas it was not for patients with only
one vascular segment affected compared with patients with-
out plaque (adjusted HR= 1.10, 95% CI = 0.13 to 9.08,
P= 0.932). If patients with coexistent carotid and femoral
artery plaque were compared with patients with only one
vascular segment affected, the adjusted HR was 5.59 (95%
CI = 0.86 to 36.16, P = 0.071). After dichotomization of
the variable to improve the Cox regression analysis
(model 2), the adjusted HR for CVEs in patients withTable 8 Explorative analysis of potential predictors of cardiov
systemic lupus erythematosus patientsa
SSc and SLE
Variable Beta coeffici
SSc versus SLE −0.173
Age (per 5 years) 0.262
Male sex 2.833
Carotid and femoral artery plaque
Group 3 (CP and FP) versus group 1 (no plaque) 2.595
Group 3 (CP and FP) versus group 2 (CP or FP) 2.672
Group 2 (CP or FP) versus group 1 (no plaque) −0.077
Arterial hypertension 1.678
Nicotine use (per 5 pack-years) 0.143
Coronary heart disease 2.592
Age at diagnosis (per 5 years) 0.075
C-reactive protein (per mg/dl) 0.220
CI, confidence interval; CP, carotid artery plaque; FP, femoral artery plaque; SLE, sys
aOnly variables suggested for multivariate Cox regression analysis are reported; comcoexistent carotid and femoral plaques was 5.92 (95%
CI = 1.55 to 22.67, P = 0.009) compared with other
patients (with only carotid plaque, only femoral plaque
or without plaque). Additionally, baseline coronary
heart disease (adjusted HR = 10.19, 95% CI = 3.04 to
34.17, P < 0.001) and male sex (adjusted HR = 8.78, 95%
CI = 2.73 to 28.19, P < 0.001) were independently associ-
ated with incident CVEs whereas arterial hypertension,
age, age at diagnosis and nicotine pack-years were asso-
ciated only in univariate analysis but not multivariate
analysis (Table 9).ascular events during follow-up in systemic sclerosis and
(n = 129)
ent Unadjusted hazard ratio (95% CI) P value
0.84 (0.33 to 2.10) 0.712
1.30 (1.10 to 1.54) 0.003
17.00 (5.99 to 48.22) <0.001
13.40 (2.99 to 59.95) <0.001
14.47 (2.51 to 83.55) 0.003
0.93 (0.12 to 7.39) 0.942
5.35 (1.91 to 15.02) <0.001
1.15 (1.04 to 1.28) 0.005
13.36 (4.67 to 38.20) <0.001
1.20 (1.04 to 1.39) 0.014
1.25 (0.98 to 1.59) 0.079
temic lupus erythematosus; SSc, systemic sclerosis.
plete report available in Additional file 3.
Table 9 Multivariate Cox regression analysis of predictors of incident cardiovascular events during follow-up in
systemic sclerosis and systemic lupus erythematosus patients
Variable Beta coefficient Adjusted hazard ratio (95% CI) P value
Cox model 1 – SSc and SLE (n = 129)a
Coronary heart disease 2.326 10.24 (3.04 to 34.55) <0.001
Male sex 2.172 8.78 (2.73 to 28.19) <0.001
Carotid and femoral artery plaque
Group 3 (CP and FP) versus group 1 (no plaque) 1.812 6.13 (1.27 to 29.53) 0.024
Group 2 (CP or FP) versus group 1 (no plaque) 0.092 1.10 (0.13 to 9.08) 0.932
Cox model 2 – SSc and SLE (n = 129)b
Coronary heart disease 2.322 10.19 (3.04 to 34.17) <0.001
Male sex 2.172 8.78 (2.73 to 28.19) <0.001
Carotid and femoral artery plaque
Group 3 (CP and FP) versus all other (CP or FP or no plaque) 1.778 5.92 (1.55 to 22.67) 0.009
Group 1, patients without carotid or femoral artery plaque; group 2, patients with only carotid or only femoral artery plaque; group 3, patients with coexistent
carotid and femoral artery plaque. CI, confidence interval; CP, carotid artery plaque; FP, femoral artery plaque; SLE, systemic lupus erythematosus; SSC, systemic
sclerosis. aZero observations excluded from model because of missing values. Events per variable: 19/4 = 4.75. bZero observations excluded from model because
of missing values. Events per variable: 19/3 = 6.33.
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Intima-media thickness as surrogate marker of
atherosclerosis in the general population
Measurement of intima-media thickening in the CCA is
a widespread accepted surrogate marker for subclinical
atherosclerosis [32,33], although the clinical importance for
the individual patient was recently challenged in the general
population [34,35]. Although the assessment of both IMT
and atherosclerotic plaques is recommended for epidemio-
logical trials studying cardiovascular disease, it is important
to keep in mind that IMT not only represents subclinical
atherosclerosis but is also influenced by nonatherosclerotic
remodeling [27]. Presence of plaque is of overriding import-
ance in reflecting cardiovascular risk [36,37].
What is the rationale to determine a fixed definition of
pathological increased intima-media thickness?
Although the term pathologic IMT is widely used, it is not
well defined. According to the guidelines of the European
Society of Cardiology, pIMT is defined as a focal IMT
>0.9 mm, regardless of gender [24]. Different cutoff values
were reported in several studies, ranging between IMT
≥1.0 mm and ≥1.18 mm for prediction of CVEs [38-40].
However, a fixed definition does not take regard of an in-
crease in IMT with older age and differences between
men and women, which is well documented in large stud-
ies [26]. For the German population only one small study
reports reference values with respect to age and gender for
pIMT: a cIMT> 1.0 mm in men 40 to 70 years old, cIMT>
0.85 mm in women 40 to 54 years old and cIMT> 1.0 mm
in women 55 to 70 years old were defined as pIMT [25].
In SLE patients, Thompson and colleagues evaluated a
mean IMT progression rate of 0.011 mm/year, which was
comparable with the IMT progression rate in controls [4].These rates also seem comparable with the rate of mean
IMT progression in healthy controls evaluated in the large
ARIC study of approximately 0.01 mm/year [26]. In our co-
hort, with respect to the results of baseline linear regression
analysis, carotid IMT increased slightly less with 0.007 mm
and 0.006 mm per age year in SSc and SLE patients, re-
spectively. For that reason, in addition to the fix definition
of pIMT given by the European Society of Cardiology [24],
we also used an age-adjusted and sex-adjusted definition of
pIMT for the German population [25], and calculated an
"ARIC definition" for pIMT, defined by the 90th percentile
of a large cohort from the ARIC study [26].
Is carotid intima-media thickness measurement a useful
parameter for atherosclerosis assessment in SSc and
SLE patients?
Previous studies in SSc and SLE patients showed a
marked heterogeneity in IMT results, raising the question
of whether IMT measurement is generally useful in these
disease entities. Two recent meta-analyses reported a mod-
erate statistically significant increased IMT in SSc and SLE
patients compared with healthy controls [1,2]. However, the
clinical relevance of these findings is questionable because
the "thickened" IMT of SSc and SLE patients seems to be
within the range of normal values, and the mean IMT of
controls was surprisingly low in some studies (and none
of these studies analyzed the predictive value for CVEs).
Moreover, most of the included studies in these meta-
analyses primarily searched for a difference in IMT in the
CCA, but atherosclerotic plaques at the bulb, ICA and
ECA were not evaluated. Additionally, it is unclear whether
other studies were not published because they also primar-
ily focused on cIMT without looking for plaques and found
no difference in cIMT (publication bias).
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patients that atherosclerotic plaques frequently occur
without a thickened intima-media, regardless of how the
definition of pIMT was applied. Our observed frequency
of atherosclerotic plaques is consistent with studies of
larger patient cohorts in SSc [10,12,15] and SLE [3-5].
The currently largest case–control study in 111 SSc pa-
tients by Nordin and colleagues reported a 48% frequency
of plaques in patients compared with 41% in controls [10],
but the prevalence of atherosclerotic plaques in SSc might
have been underestimated when ultrasound examination
did not include the ICA and ECA and by application of an
unusual definition of plaque as IMT >1 mm and 100%
increase of IMT compared with the adjacent wall. In con-
trast, Lukjanowicz and colleagues reported an increased
frequency of atherosclerotic plaques in 25 of 62 SSc
patients (40.3%) compared with no plaques in 30 healthy
controls, also without any signs of intima-media thickening
in SSc patients, which supports our observations (results
published as abstract, details of ultrasound examination are
unknown) [11,12].
In SLE patients, Roman and colleagues (n = 197) [3],
Thompson and colleagues (n = 217) [4] and Anania and
colleagues (n = 114) [5] reported a frequency of 37 to 43%
carotid artery plaques compared with 15 to 30% in healthy
controls, and found no difference [4,5] or even a lower
cIMT [3] in SLE patients. In large studies without compari-
son with healthy controls, Manzi and colleagues (n = 175)
[41] and Kao and colleagues (n = 392) [20] have observed
carotid plaques in 30 to 40% of SLE patients.
Carotid atherosclerosis is thus frequent and may have
been previously underestimated in both connective tissue
diseases, when only cIMT was measured. An extension of
carotid ultrasound examination distal to the CCA segment
for plaque assessment is highly recommended, because
the majority of plaques are localized distant to the CCA
(only ~5% of plaques) at the region of the bulb (~40%),
ICA (~45%) and ECA (~10%). Additionally, the use of a
common definition of atherosclerotic plaque would be
desirable to achieve comparable results between further
studies [27].Is carotid intima-media thickness measurement a useful
parameter for prediction of cardiovascular events in SSc
and SLE patients?
In general, the discrepancy between manifest atheroscler-
otic plaques and the absence of intima-media thickening
raises the question of whether IMT measurement is useful
in clinical routine care of SSc and SLE patients. With re-
spect to clinically relevant atherosclerosis (that is, predict-
ive of CVEs), IMT measurement was not as useful as
detection of plaques for predicting CVEs in our cohort.
Even if patients with incident CVEs have a higher baselinecIMT, as observed in a one large cohort of SLE patients
(0.80 vs. 0.64 mm) [20], they would not have been identi-
fied as at risk of CVEs in routine clinical care if this in-
crease does not fulfill the definition of pathologic IMT.
Moreover, in accordance with our results, this large cohort
study by Kao and colleagues in SLE patients revealed that
assessment of plaques is more important than measure-
ment of IMT for risk prediction of incident CVEs (HR
4.26 vs. 1.35, respectively). In SSc patients, large cohort
studies of CVEs including atherosclerotic plaque assess-
ment are lacking. Our data suggest that in SSc patients the
detection of atherosclerotic plaques but not IMT is of clin-
ical relevance in predicting CVEs as well.
Is additive femoral artery sonography useful to evaluate
atherosclerosis and to identify SSc and SLE patients at
risk of cardiovascular events?
Our results of plaque localization, representing differences
between left and right sides as well as carotid and femoral
artery plaque presence, underline the results of Belcaro
and colleagues [16], who showed the necessity of bilateral
carotid and femoral artery examination to estimate the
presence of atherosclerosis accurately (in accordance with
carotid arteries, the evaluation of atherosclerotic plaques
seems to be more useful than the evaluation of IMT in
femoral arteries). Furthermore, in concordance with the
results of Belcaro and colleagues [16], the combined as-
sessment of carotid and femoral artery plaques predicted
significantly more CVEs during follow-up than the meas-
urement of only one vascular segment. With respect to
confounder-adjusted hazards, patients with coexistent ca-
rotid and femoral artery plaque had an approximate HR of
6 in contrast to patients with only carotid or only femoral
artery plaque as well as in contrast to patients without
plaque. In comparison, Kao and colleagues observed a HR
of 4.3 for carotid plaque predictive of "hard" CVEs in SLE
patients [20] but did not assess the femoral arteries. In our
cohort of SSc and SLE patients, if we did not account for
coexistent femoral artery atherosclerosis, we would have es-
timated a confounder-adjusted HR of 3.5 for carotid plaque
predictive of CVEs (data shown in Additional file 3). The
risk of CVEs by presence of carotid artery plaque would
thus have been overestimated in patients without plaque
and underestimated in patients with unknown coexistence
of femoral artery plaque. Taken together, additional screen-
ing of the femoral artery is very useful to identify SSc and
SLE patients at high risk.
Association of atherosclerosis with traditional and
nontraditional cardiovascular risk factors, immunosuppressive
medications and SSc and SLE specific variables
In SLE, previous studies have reported several traditional
cardiovascular risk factors such as age, male sex, arterial
hypertension, obesity, dyslipidemia and family history, but
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activity, damage score, renal involvement and prednisolone
use to be associated with atherosclerosis [3,4,42-53]. There
is still a controversial debate as to whether accelerated ath-
erosclerosis is or is not a feature of SSc [8,9]. However, in
studies indicating a higher prevalence of atherosclerosis in
SSc, an association with age, arterial hypertension, trigly-
ceride levels, smoking, disease duration and cumulative
CS dosage was observed [10,54,55]. In our cohort in uni-
variate analysis, age, male gender, postmenopausal status
in women, arterial hypertension, dyslipidemia and nicotine
pack-years were associated with atherosclerotic plaques.
Moreover, the presence of plaque was associated with a
higher age at diagnosis, but not with disease duration in
both patient groups. There was no association with
illness-specific activity and damage scores such as the
Systemic Lupus Erythematosus Disease Activity Index and
the Systemic Lupus International Collaborating Clinics
damage index in SLE, or the modified Rodnan Skin Score
in SSc patients. Notably, age was the strongest factor asso-
ciated with CCA and CFA IMT. Furthermore, postmeno-
pausal status correlated with CCA IMT, and nicotine
pack-years with CFA IMT, whereas other cardiovascular
risk or disease-related factors did not. In multiple logistic
regression analysis, age and nicotine pack-years were inde-
pendently associated with atherosclerotic plaque occur-
rence over all patients. Additionally, in SSc patients the
cumulative prednisolone dose was associated with athero-
sclerotic plaque, supporting the idea that prednisone use
may be a deteriorating factor for atherosclerosis in SSc
[55]. In SLE patients, corticosteroids have shown to in-
crease cardiovascular risk factors such as arterial hyper-
tension and body weight, whereas HCQ leads to a
decrease of serum cholesterol levels [56]. Moreover, CYP,
HCQ and CS use seem to be associated with a lower fre-
quency of atherosclerotic plaque in SLE patients [49].
However, in our smaller cohort we found no significant
differences in CYP, HCQ or CS medication between SLE
patients with or without atherosclerotic plaque.
Interestingly, in multivariate analysis AZA use seemed
to be associated with atherosclerotic plaques in SLE
patients. AZA was recently found to be associated with an
increased cIMT in pediatric SLE patients [47] and with
vascular events in adult SLE patients [57]. Because of the
limited number of SLE patients available for follow-up
analysis in our cohort we were not able to analyze AZA as
contributing risk factor for CVEs.
Association of autoantibodies with atherosclerosis in SSc
and SLE
High titers of antinuclear antibodies were found to be asso-
ciated with coronary atherosclerosis [58]. In our cohort,
current or former ANA were not associated with IMT, and
neither were with the presence of atherosclerotic plaque.Antiphospholipid antibodies are supposed to activate endo-
thelial cells and are hence suspected to accelerate the ath-
erosclerosis process [59], and different other autoantibodies
were reported to correlate with cardiovascular disease in
SLE. Roman and colleagues found anti-Sm, anti-RNP and
anticardiolipin antibodies significantly more often in SLE
patients without compared with those with carotid artery
plaque [49]. Similarly, other studies reported that Sm anti-
bodies may have cardioprotective effects and were less
often observed in SLE patients with coronary atheroscler-
osis or carotid artery plaque [52,60]. In our cohort, we
found no difference in atherosclerotic plaque frequency
between SLE patients with or without anti-Sm or anticar-
diolipin antibodies. Recently, dsDNA antibodies were
suggested to contribute to noncalcified coronary plaque
[44]. In contrast, in our cohort dsDNA antibodies were
found less frequently in patients with atherosclerotic pla-
ques in univariate analysis, but were not confirmed in
multivariate analysis (which can be explained by the fact
that dsDNA antibodies occurred more often in older SLE
patients in our cohort). Surprisingly, in multivariate ana-
lysis absence of the less disease-specific ssDNA antibodies
did qualify as a statistically significant independent pre-
dictor for atherosclerotic plaque in SLE patients. We found
no confounder that can explain this unexpected finding;
this observation may be verified in further studies.
Atherosclerosis was found more often in anti-centromere
antibody-positive SSc patients [10], and coronary artery
calcification less often in anti-SCL70 antibody-positive SSc
patients [61]. Coronary flow reserve was reported to be
lower in diffuse cutaneous SSc patients [62], perhaps due to
microvascular involvement rather than atherosclerosis [8].
In SSc patients of our cohort, atherosclerosis was also
found more often in the limited than diffuse cutaneous
subtype, hence centromere antibody was found more often
and SCL70 antibody less often in patients with atheroscler-
otic plaque. However, these findings in our cohort were due
to the older age of patients with centromere antibodies
compared with patients with Scl-70 antibodies; after adjust-
ment for age there was no statistically significant difference
(data not shown).Limitations of the study
Whether the number of patients with plaque from the SSc
and SLE patients was high enough to build two separate
logistic regression models with a suitable number of events
per variable, it was not for Cox regression and the analysis
of both diseases was combined to ensure at least five
patients with CVEs per variable [63,64]. We are confident
that this combined analysis was feasible because we did not
observe a significant difference in the frequency or distribu-
tion of atherosclerotic plaque nor in the incidence of CVEs
between SSc and SLE patients. However, we were not able
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and SLE patients.
The higher follow-up rate of SSc patients (87%) than
SLE patients (51%) might be explained by the inclusion
of SSc patients in the German network for SSc. Because
the loss of follow-up in SLE patients (49%) could have
biased our findings, we analyzed whether risk factors for
CVEs were more or less prevalent in SLE patients with-
out follow-up: SLE patients available for follow-up ana-
lysis had at baseline a slightly shorter disease duration
(mean 5 years vs. 6 years), no difference in SLICC dam-
age index score (median 2 vs. 2) and a slightly higher
SLEDAI (median 12 vs. 8) compared with patients with-
out follow-up. Baseline coronary heart disease was
prevalent in 3/51 (5.9%) SLE patients available versus 6/
49 (12.2%) SLE patients nonavailable for follow-up, male
sex in 4/51 (7.8%) versus 9/49 (18.4%) and coexistence
of carotid and femoral artery plaques in 12/51 (23.5%)
versus 13/49 (26.5%) patients, respectively. SLE patients
without follow-up were thus most probably at a slightly
higher risk for CVEs and we might have underestimated
the true incidence of CVEs in SLE patients. On the other
hand, the incidence of CVEs in our SLE cohort was
higher compared with previous larger cohort studies of
SLE patients [18-20]. This difference might be based on
unequal study populations, due to a varying definition of
CVEs, and patients without follow-up may have been
more likely than those without development of CVEs or
who died due to other causes (in this scenario we might
have overestimated the "true" incidence of CVEs in SLE
patients).
However, besides these limitations our study primarily
focused on the value of duplexsonography evaluation
and demonstrated the uselessness of IMT measurement
in contrast to plaque assessment and highlighted the
value of additive femoral artery screening for assessment
of atherosclerosis and to identify SSc and SLE patients at
high risk of incident CVEs. Larger prospective studies
are required to estimate the "true" incidence of CVEs
and to evaluate further potential risk factors for CVEs,
particularly in SSc patients.
Conclusions
In summary, our study demonstrates a high frequency of
atherosclerotic plaques in the carotid arteries as well as
in the femoral arteries in the absence of a pIMT in both
SSc and SLE patients. IMT measurement appears to be
less useful than searching for atherosclerotic plaques in
SSc and SLE patients in routine cardiovascular assess-
ment. Sonography of both carotid and femoral arteries
to assess atherosclerotic plaques provides a more accur-
ate evaluation of clinically relevant atherosclerosis than
only carotid artery screening in order to reduce the over-
all morbidity and mortality in affected patients.Additional files
Additional file 1: Is a table presenting correlation of carotid and
femoral artery IMT with traditional and nontraditional risk factors
for atherosclerosis. A detailed report of correlations between mean
common carotid IMT and mean femoral artery IMT with traditional and
nontraditional risk factors for atherosclerosis in SSc and SLE patients.
Additional file 2: Is a table presenting explorative univariate
analysis of potential risk factors between patients with or without
atherosclerotic plaques. A detailed report of explorative univariate
analysis of the association of traditional cardiovascular and disease-related
risk factors with presence of atherosclerotic plaques in SSc and SLE patients.
Additional file 3: Is tables presenting explorative analysis and
additional multivariate Cox regression analysis of predictors of
incident CVEs during follow-up in SSc and SLE patients. The first
table shows a detailed report of explorative analysis of predictors of CVEs
during follow-up in SSc and SLE patients. The second table shows
additional multivariate Cox regression analysis of predictors of incident
CVEs during follow-up in SSc and SLE patients including only carotid but
not femoral artery plaques (if only carotid artery duplexsonography was
performed and status of femoral artery plaque was unknown).
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